CG
RNTX

Colony Group’s Rein Therapeutics RNTX Stock Holding History

Colony Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,516
Closed -$19K – 897
2022
Q3 		$19K Hold
4,516
– – ﹤0.01% 769
2022
Q2 		$23K Hold
4,516
– – ﹤0.01% 812
2022
Q1 		$46K Buy
+4,516
New +$40.9K ﹤0.01% 830

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Colony Group's RNTX Position: Q4 2022 in Review

Colony Group sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 4,516 shares — an estimated $19K sold.

Colony Group first reported a position in RNTX in Q1 2022 and held it in 3 quarters. The position peaked at $46K in Q1 2022. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

  • Colony Group reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Colony Group sold 4,516 Rein Therapeutics shares in Q4 2022, an estimated $19K.
  • Colony Group first reported a position in Rein Therapeutics in Q1 2022 and held it in 3 quarters.
  • Colony Group's Rein Therapeutics position peaked at $46K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on Colony Group's 13F filing for Q4 2022, filed 14 Feb 2023.